

Superinduction of Cyclooxygenase-2 Activity in Human Osteoarthritis-affected Cartilage

Influence of Nitric Oxide

Ashok R. Amin,*^{§||} Mukundan Attur,* Rajesh N. Patel,* Geeta D. Thakker,* Paul J. Marshall,** John Rediske,** Steven A. Stuchin,[‡] Indravadan R. Patel,* and Steven B. Abramson*[§]

*Department of Rheumatology, [‡]Department of Orthopedic Surgery, Hospital for Joint Diseases, New York 10003; [§]Department of Medicine, ^{||}Department of Pathology, [¶]Kaplan Cancer Research Center, New York University Medical Center, New York 10016; and

**Ciba-Geigy Corporation, Summit, New Jersey 07901

Abstract

Cartilage specimens from osteoarthritis (OA)-affected patients spontaneously released PGE₂ at 48 h in ex vivo culture at levels at least 50-fold higher than in normal cartilage and 18-fold higher than in normal cartilage + cytokines + endotoxin. The superinduction of PGE₂ production coincides with the upregulation of cyclooxygenase-2 (COX-2) in OA-affected cartilage. Production of both nitric oxide (NO) and PGE₂ by OA cartilage explants is regulated at the level of transcription and translation. Dexamethasone inhibited only the spontaneously released PGE₂ production, and not NO, in OA-affected cartilage. The NO synthase inhibitor HN^G-monomethyl-L-arginine monoacetate inhibited OA cartilage NO production by > 90%, but augmented significantly (twofold) the spontaneous production of PGE₂ in the same explants. Similarly, addition of exogenous NO donors to OA cartilage significantly inhibited PGE₂ production. Cytokine + endotoxin stimulation of OA explants increased PGE₂ production above the spontaneous release. Addition of L-NMMA further augmented cytokine-induced PGE₂ production by at least fourfold. Inhibition of PGE₂ by COX-2 inhibitors (dexamethasone or indomethacin) or addition of exogenous PGE₂ did not significantly affect the spontaneous NO production. These data indicate that human OA-affected cartilage in ex vivo conditions shows (a) superinduction of PGE₂ due to upregulation of COX-2, and (b) spontaneous release of NO that acts as an autacoid to attenuate the production of the COX-2 products such as PGE₂. These studies, together with others, also suggest that PGE₂ may be differentially regulated in normal and OA-affected chondrocytes. (*J. Clin. Invest.* 1997; 99:1231–1237.) Key words: nitric oxide • osteoarthritis • cyclooxygenase • cytokine • cartilage

Introduction

Osteoarthritis (OA)¹ is a disease that affects the weight-bearing joints and peripheral and axial articulations. The clinical correlates are pain and restricted motion (1), and although the disease is classified as a noninflammatory arthropathy, several inflammatory components have been implicated in the disease process and have been observed in the synovial fluid. These include inflammatory cytokines, immunoglobulins, and other mediators in the joints (2, 3). Increased production of acute phase reactants such as transferrin, ceruloplasmin, acid glycoprotein, and increased concentrations of substance P have also been reported in OA (4). One of the hallmarks of OA is the progressive degeneration of the cartilage, where the synthetic and degradative forces are operating in tandem. Unchecked, the process leads to an imbalance of these forces and joint destruction.

Prostaglandins are produced at elevated levels in inflamed tissues including rheumatoid synovium (5, 6). PGE₁ and PGE₂ contribute to synovial inflammation by increasing local blood flow and potentiating the effects of mediators such as bradykinin and IL-1 β that induce vasopermeability (7). PGE₂ has also been shown to trigger osteoclastic bone resorption (8), suggesting that this molecule may contribute to the pathophysiology of joint erosion in RA.

The human articular chondrocytes, when stimulated with cytokines and/or endotoxin in vitro, release various inflammatory mediators, including nitric oxide (NO) and PGE₂ (9, 10). We (11) and others (12) have recently observed that OA-affected cartilage in ex vivo conditions spontaneously releases NO in quantities sufficient to cause cartilage damage. The importance of these findings is supported by experiments conducted in animal models of arthritis, where inhibitors of NO synthase (NOS) (13, 14) or cyclooxygenase (COX)-2 (15) can independently repress joint inflammation, concomitant with the attenuation of PGE₂ or NO synthesis. In the present study, we report that OA-affected cartilage (but not normal cartilage): (a) spontaneously releases PGE₂ and NO, which are coordinately regulated; and (b) shows upregulated COX-2 mRNA and COX-2 protein, which spontaneously releases substantial amounts of PGE₂ in ex vivo conditions. Furthermore, the NO produced by the OA-affected cartilage inhibits the autocrine (or cytokine + endotoxin-induced) PGE₂ production, thus indicating a negative effect of NO on PGE₂ synthesis.

Address correspondence to Ashok R. Amin, Department of Rheumatology, Room 1600, Hospital for Joint Diseases, 301 E. 17th Street, New York, NY 10003. Phone: 212-598-6537; FAX: 212-598-6168.

Received for publication 7 October 1996 and accepted in revised form 19 December 1996.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/97/03/1231/07 \$2.00

Volume 99, Number 6, March 1997, 1231–1237

1. Abbreviations used in this paper: COX-2, cyclooxygenase-2; L-NMMA, HN^G-monomethyl-L-arginine monoacetate; NF, nuclear factor; NO, nitric oxide; NOS, NO synthase; OA, osteoarthritis; PDTC, pyrrolidine dithiocarbamate; RT, reverse transcription.

Methods

Reagents and cell lines. A macrophage-like cell line, RAW 264.7, was obtained from American Type Culture Collection (Rockville, MD). Monoclonal α -mouse macrophage COX-2 antibody, which also cross-reacts with human COX-2, was obtained from Transduction Laboratories (Lexington, KY). Protease inhibitors, dexamethasone, cycloheximide, indomethacin, pyrrolidine dithiocarbamate (PDTC), aminoguanidine, sodium nitroprusside, and LPS were obtained from Sigma Chemical Co. (St. Louis, MO); human IL-1 β and TNF- α were from Fisher Scientific Co. (Pittsburgh, PA); and H^NG-monomethyl-L-arginine monoacetate (L-NMMA) from Cyclo₃pss BioChemical Corp. (Salt Lake City, UT).

Procurement of human cartilage. Cartilage slices were taken from the knees of patients with the diagnosis of advanced OA (age: 50–70 yr) who were undergoing knee replacement surgery, and from nonarthritic knees (normal controls: age 20–40 yr). The OA patients were free of steroidal/nonsteroidal antiinflammatory drugs for at least 2 wk before surgery. Nonarthritic knee cartilage was obtained from patients with fractures or from accident victims after knee amputation the same day.

Extraction of human cartilage COX-2 and Western blotting. Slices from articular cartilage were frozen at -70°C , milled to fine particulate in liquid nitrogen, and sequentially extracted (10 ml/g wet wt tissue) with neutral salt buffer (Tris HCl:saline) containing protease inhibitors (11). Samples were run on 10% SDS-PAGE gels under nonreducing conditions, transferred to nitrocellulose, and Western blotted with α -COX-2 antibody. Bound antibody was detected by a secondary antibody conjugated with horseradish peroxidase, and developed using the enhanced chemiluminescence Western blotting system (Amersham Corp., Arlington Heights, IL) on Kodak Xomatic x-ray film.

Determination of nitrite/PGE₂. NO production was measured by estimating the stable NO metabolite, nitrite, in conditioned medium by modified Griess reaction (16). PGE₂ (detection limit: 50 pg/ml) was determined in the culture supernatant using RIA Kit (Sigma Chemical Co.) according to the manufacturer's instructions.

RNA extraction from articular chondrocytes. The method we followed is basically as described by Adams et al. (17). The cartilage was milled into fine powder in liquid nitrogen and extracted with 4 M guanidium thiocyanate, 25 mM sodium citrate, 0.5% sodium dodecyl sarcosine, and 0.1 M 2-mercaptoethanol for 4 h on a rocker. It was then extracted with H₂O-saturated phenol followed with phenol/chloroform. The aqueous layer was layered onto cesium trifluoroacetate gradient for ultracentrifugation (24,000 rpm/24 h). The RNA pellet was dissolved in GuSCN and precipitated with alcohol in the presence of acetic acid. The RNA obtained with this method is pure enough for reverse transcriptase (RT)-PCR analysis.

RT-PCR analysis, cloning and sequencing. The presence of mRNA was analyzed by RT of total RNA (1 μg) followed by PCR amplification of the cDNA. The PCR was carried out in an automated DNA thermal cycle (Perkin-Elmer Cetus Instruments, Norwalk, CT). The cDNA from mRNA was prepared using a SuperScriptTM RNase H Reverse Transcriptase (Gibco BRL, Gaithersburg, MD) and PCR amplification was performed in 50 μl solution containing 1.5 mM MgCl₂, 0.4 μM of each primer, 0.2 mM of each dNTP, 2.0 units of Taq DNA polymerase (Promega Corp., Madison, WI). The cycle conditions were 45 s at 94°C , 45 s at 60°C , and 2 min at 72°C for 20–30 cycles for both COX-2 and β -actin. The PCR product was analyzed by electrophoresis on 1.5% agarose gels. Verification that the amplified PCR product originated from RNA rather than DNA was accomplished by preparing duplicate RNA samples both untreated and treated with reverse transcriptase, followed by PCR amplification. The amplified PCR products were directly cloned into PCRTM II Prokaryotic TA Cloning System (Invitrogen, San Diego, CA), and then the sequence of clones was determined using M13 primers by the dideoxy chain termination method using an automated laser fluorescent DNA sequencer (ALF; Pharmacia Diagnostics, Piscataway, NJ).

Statistical analysis. The data represent a minimum of two experiments performed from separate normal individuals or OA patients. All experiments using cartilage slices were performed in triplicate or quadruplicate for each parameter studied. The *P* value was calculated using Student's *t* test between the parameters in the same experiment.

Results

Previous studies have shown that stimulation of articular cartilage leads to synthesis of (in order of decreasing quantity) PGE₂, PGF₂ α , PGI₂, and TXA₂ (18). A number of synovial cytokines, including IL-1 β and TNF- α , or endotoxins (LPS) enhance PGE₂ and NO synthesis in cultured chondrocytes (9, 10). In the present study, we first examined whether cartilage slices from normal human cartilage responded in a similar fashion. Incubation of normal human cartilage slices with IL-1 β + TNF- α + LPS caused a significant augmentation in PGE₂ and induction of NO production within 48 h in culture (Fig. 1). These experiments were consistent with previous observations of basal levels of PGE₂ released by normal chondrocytes (unlike NO production) that could be augmented with LPS or IL-1 β (10). These experiments demonstrate that the isolated chondrocytes and those embedded in cartilage in vitro behaved similarly with respect to the simultaneous stimulation of NO and PGE₂ production. We next examined whether PGE₂ was also spontaneously released by the OA-affected cartilage in ex vivo conditions, as we have previously reported for NO (11). Indeed, all the OA-affected cartilage (samples from 10 different patients) spontaneously released both NO (44–265 μM) and PGE₂ (50–670 ng/ml per g tissue) in ex vivo conditions at 48 h (Fig. 2). Each of the samples tested, as expected, had high levels of NO spontaneously released in the culture medium, as previously observed (11). It should be noted that the lowest amount of PGE₂ spontaneously released (Fig. 2, patient 2, ~ 50 ng/ml) was at least 10-fold higher than that produced by normal cartilage (Figs. 1 and 2) or spontaneously released by equivalent amounts of normal chondrocytes (10). Next, using various inhibitors, we examined whether the spontaneous production of PGE₂ by OA-affected cartilage was due to endogenous upregulation of the inducible COX-2. The release of both these mediators (NO and PGE₂) was sensitive to nuclear-factor (NF)- κB transcription factor inhibitor




Figure 1. Modulation of NO and PGE₂ production in normal cartilage organ cultures. Normal knee articular cartilage from one individual was cut into 3-mm disks, and four to six disks were placed in organ

cultures (in triplicate) of 2 ml media in the presence and absence of IL-1 β (1 ng/ml) + TNF- α (100 U/ml) + LPS (100 $\mu\text{g}/\text{ml}$). The levels of nitrite and PGE₂ were monitored at 48 h as described in Methods. Data are expressed as micromolar of nitrite or nanograms per milliliter of PGE₂ per gram (wet wt) of cartilage. The *P* values based on the triplicate data (*n* = 3) between control (unstimulated) and cytokine + endotoxin-treated cultures were < 0.001 for PGE₂ production and < 0.0001 for nitrite accumulation. ND, not detectable (< 0.1 μM nitrite). Data represent one of three similar experiments.




Figure 2. Spontaneous release of PGE₂ from OA-affected cartilage. Knee articular cartilage from 10 patients undergoing knee replacement surgery was set up in organ culture in triplicate ($n = 3$) as described in Fig. 1, without any modulators. Levels of nitrite/PGE₂ were monitored after

48 h, as shown in upper panel. The dotted line represents the mean amount of PGE₂ released by these 10 patients, which was 285 ng/ml per g tissue. Data are expressed as micromolar of nitrite or nanograms per milliliter of PGE₂ per gram (wet wt) of cartilage accumulated in the same medium at 48 h.

PDTC and translation inhibitor cycloheximide (Fig. 3), indicating the inducible nature of these mediators.

Since recent studies have implicated NF- κ B as one of the essential transcription factors for the inducible COX-2 transcription (19), we examined the expression of inducible COX-2 mRNA directly from cartilage obtained from normal and OA-affected patients. Fig. 4, A and B, shows that all nine OA-






Figure 3. Comparison of NO and PGE₂ spontaneously produced by OA-affected cartilage. OA-affected knee articular cartilage from one patient was cut into 3-mm disks, and four to six disks were placed in organ cultures (in triplicate) in 2 ml of F-12 medium in the presence and absence of PDTC (20 μ M) or cycloheximide (2 μ g/ml). The levels of nitrite and PGE₂ were monitored after 48 h. Data are expressed as micromolar of nitrite or nanograms per milliliter of PGE₂ per gram (wet wt) of cartilage; $n = 3$. The P values between control (spontaneous release) versus PDTC-treated (nitrite < 0.0024 ; PGE₂ < 0.0024) or cycloheximide-treated cultures (nitrite < 0.0001 ; PGE₂ < 0.0011) were calculated. ND, not detectable ($< 0.1 \mu$ M nitrite). The data represent one of two similar studies.

affected cartilage samples tested showed upregulated COX-2 mRNA that could not be detected in the three normal cartilage samples tested, where the β -actin signal could be seen with the same mRNA preparations (not shown for Experi-



A



B

C

Figure 4. Expression of COX-2 and β -actin mRNA in normal and OA-affected cartilage. (A) Normal and OA-affected cartilage from different individuals was extracted for total RNA immediately upon receiving the samples without releasing the cells, as described in Methods. Equal amounts (100 ng) of total RNA were subjected to RT-PCR analysis (30 cycles) using specific human COX-2 primers (5'-TTCAAATGAGATTGTGGGAAAAT 3' and 5'-AGATC ATCTCTGCCTGAGTATC-TT 3') which generated a 303-bp fragment (20). The same RNA preparation (100 ng) was also subjected to RT-PCR analysis of β -actin using the primers 5'-GTGGGGCGCCCCAGGC ACCA 3' and 5'-CTCCTTAAT-GTCACGCACGATTTC 3' which generated a 475-bp fragment. The PCR primers designated here span one exon and two introns (20). STD designates mol wt standards. In one of the experiments (Experiment I), RT-PCR analysis of RNA from patient 4 was carried out without the reverse transcriptase enzyme (RT:Control), thus indicating the lack of potential DNA

contamination. +Control designates amplification of COX-2 from a standard COX-2 cDNA. (B and C) The 303-bp COX-2 fragment amplified from the RNA of patient 9 (as shown in Experiment II) was cloned into a TA-cloning vector (ClonTech, Palo Alto, CA) and sequenced; it is compared above with the human COX-2 sequence (M90100).




Figure 5. Western blot analysis of COX-2 from OA-affected cartilage. RAW 264.7 cells were stimulated with LPS to induce COX-2 as previously described (21). The cell-free extract was loaded on the SDS

gel as shown in lane 1. Total cartilage extract from the OA-affected cartilage was made as described in Methods and loaded onto the gel as shown in lane 2. It was then Western blotted and probed with an anti-COX-2 mAb that binds to both murine and human COX-2, giving a signal at 72 kD.

ment II). The identity of the COX-2 mRNA was confirmed by Southern blot analyses of the 303-bp COX-2 fragments using a full-length COX-2 cDNA (data not shown) and sequencing one of the fragments from COX-2 mRNA amplified from OA-affected cartilage, as shown in Fig. 4, B and C. The partial DNA sequence of the OA-COX-2 obtained from one of the OA patients (*Experiment II*) showed > 98% homology with the known human COX-2 sequence (20). The expression of COX-2 was confirmed by Western blotting of COX-2 protein from OA-affected cartilage extracts which showed the expression of a 72-kD COX-2 protein as observed in LPS-stimulated macrophages (21) (Fig. 5). These experiments indicate that OA-affected cartilage spontaneously releases an inflammatory compound, PGE₂, in levels at least 50-fold higher (on average) than the normal cartilage, and this effect may be due to transcriptional upregulation of COX-2, which is sensitive to PDTC and cycloheximide.

We next examined the effect of endogenous NO on PGE₂ production in OA-affected cartilage. OA-affected cartilage

Table I. Regulation of Spontaneously Released PGE₂ in OA-affected Chondrocytes by Endogenous NO

OA cartilage (treatment)	PGE ₂	Nitrite
	ng/ml per g wt tissue	μM/g wet wt tissue
Experiment 1		
Control +	45.4±8.1	95.0±2.8
L-NMMA (500 μM)	115.7±55.0*	6.0±3.0*
Experiment 2		
Control +	205.0±58.0	155.3±47.0
L-NMMA (500 μM)	386.0±157.0*	8.2±3.0*
Experiment 3		
Control +	136.9±35.5	46.5±7.6
L-NMMA (500 μM)	187.5±42.0‡	1.0±0.1*
Experiment 4		
Control +	347.0±79.4	207.8±105.0
L-NMMA (500 μM)	786.2±112.0*	53.5±12.2*

Knee articular cartilage from four separate OA-affected patients was individually placed in organ culture in triplicate (*n* = 3) as described in Fig. 1. The release of NO/PGE₂ in the medium was monitored after 48 h in the presence and absence of 500 μM of L-NMMA. Data are expressed as micromolar of nitrite or nanograms per milliliter of PGE₂ per gram (wet wt) of cartilage. The *P* value between the control (spontaneously released) and L-NMMA-treated cultures was within * < 0.005, ‡ < 0.07 for each individual experiment.

slices were incubated in ex vivo conditions and the levels of spontaneously released NO and PGE₂ were monitored at 48 h in the presence and absence of the competitive NOS inhibitor L-NMMA (Table I). Addition of L-NMMA blocked > 90% of spontaneous endogenous NO production in these OA-affected cartilage organ cultures, as previously reported (11). However, the decrease in the NO production caused a significant augmentation (approximately twofold) of the PGE₂ accumulation in the same experiments. These experiments indicate that the levels of endogenous NO spontaneously released in ex vivo conditions inhibit the spontaneous production of PGE₂ in the same OA-affected cartilage slices. The effects of endogenous NO in OA cartilage on PGE₂ production could be mimicked by exogenously added NO donors such as sodium nitroprusside. In one representative experiment where OA-affected cartilage had released 221.7±70.2 ng/ml of PGE₂ (per g wet wt cartilage) at 72 h, addition of 100 μM of sodium nitroprusside (at 0 h) in the same explants significantly reduced PGE₂ production to 43.3±14.7 (*P* < 0.004; *n* = 3).

We then examined the effects of COX-2 products on NO production in OA explants as shown in Fig. 6. Addition of dexamethasone or indomethacin, as expected, inhibited (> 90%) the PGE₂ production in the OA-affected cartilage but had no significant effect on the levels of NO released by the same cartilage samples. Furthermore, as expected, addition of a COX-2 inhibitor, CGP28238 (Flosulide; Ciba-Geigy Corp., Summit, NJ) at 5 μM inhibited spontaneous PGE₂ production by OA-affected cartilage in ex vivo conditions by > 95% (like indomethacin), but had no significant effect on NO production (data not shown). We also tested the effects of exogenous PGE₂ on the spontaneous accumulation of nitrite in ex vivo conditions in our OA-explant assay. The OA-affected cartilage on an average released 28 ng/ml of PGE₂/100 mg cartilage as shown in Fig. 2. We therefore added 25 or 50 ng/ml of PGE₂ to the above OA cartilage explant assay. There was no significant effect on the accumulation of nitrite in OA-explants supplemented with 25 ng/ml PGE₂ (5.9±2.7 μM nitrite at 72 h;




Figure 6. Regulation of PGE₂ production and NO in OA-affected cartilage by dexamethasone and indomethacin. Knee articular cartilage from an OA-affected patient was individually placed in organ culture (in triplicate) as described in Fig. 1. The release of NO/PGE₂ in the medium was monitored after 48 h in the presence and absence of dexamethasone (0.1–1 μM) and indomethacin (5 μM). Data are represented as micromolar of nitrite or nanograms per milliliter of PGE₂ per gram (wet wt) of cartilage. *P* values between the control and dexamethasone-treated cultures were: nitrite < 0.27, PGE₂ < 0.0001. *P* values between the control and indomethacin-treated cultures were: nitrite < 0.26, PGE₂ < 0.0001 (*n* = 3). The data represent one of two similar experiments.

Table II. Regulation of COX-2 by Intracellular NO in Cytokine + Endotoxin-stimulated OA-affected Cartilage in Ex Vivo Conditions

OA Cartilage (treatment)	PGE ₂	Nitrite
	ng/ml per g wet wt tissue	μM/g wet wt tissue
Control	205.0±58.0*	155.3±47.0 [‡]
L-NMMA (500 μM)	386.0±157.0*	8.2±3.0
PDTC (30 μM)	11.0±8.0	1.4±1.2
LPS + TNF-α + IL-1β	466.0±31.0*	240.7±36.9 [‡]
LPS + TNF-α + IL-1β + L-NMMA	1838.0±349.0*	27.3±4.6
LPS + TNF-α + IL-1β + PDTC	14.8±3.2	4.7±4.2

Cartilage from one OA-affected patient was incubated in organ culture in triplicate ($n = 3$) as described in Fig. 1 and treated with cytokines + endotoxin, PDTC, or L-NMMA for 48 h. The levels of PGE₂ and nitrite were estimated from the same medium. The data represent one of two similar experiments; $n = 3$. P values: * < 0.005 , [‡] < 0.01 .

$P < 0.30$, $n = 3$) or 50 ng/ml PGE₂ (4.2 ± 3.3 μM nitrite at 72 h; $P < 0.21$, $n = 3$) as compared to control (2.8 ± 0.6 μM at 72 h). These experiments demonstrate that in OA-affected cartilage, unlike in rat mesangial cells (22), inhibitors of PGE₂ synthesis or addition of exogenous PGE₂ had no significant effect on NO production.

We also examined the influence of cytokines and endotoxin on COX-2 expression and the effect of endogenous NO in OA-affected cartilage. As shown in Table II, production of both NO and PGE₂ in OA-affected cartilage is augmented significantly (1.6- and 2.3-fold, respectively) after exposure to LPS + TNFα + IL-1β. The inhibition of the NO production with L-NMMA under these conditions caused a dramatic (fourfold) increment in the PGE₂ accumulation, which exceeded that observed in the nonstimulated explants (Table II). As expected, PDTC blocked both the spontaneous and the cytokine + endotoxin-induced release of NO/PGE₂. These experiments indicate that the decreased levels of endogenous NO (in the presence and absence of cytokines + endotoxins + L-NMMA) in OA-affected cartilage cause a significant increase in PGE₂ production, thus again indicating that the endogenous NO released by OA-affected cartilage inhibits PGE₂ production, and could therefore act as a negative modulator of PGE₂ synthesis in OA-affected cartilage.

Discussion

These experiments raise the question: osteoarthritis or osteoarthritis? Our data indicate that the spontaneous production of PGE₂ by human OA-affected cartilage is strikingly above that produced by normal cartilage. For example, 1 g of normal human cartilage releases ~ 5 ng/ml of PGE₂ at 48 h in ex vivo conditions described in this study. Addition of cytokines + endotoxin augments this effect to ~ 15 ng/ml. However, equivalent amounts of OA-affected cartilage in ex vivo conditions (and induced in vivo) show superinduction of PGE₂ production by releasing an average of ~ 285 ng/ml/g tissue (50-fold greater than the spontaneous release and 18-fold greater

than the cytokine + endotoxin-induced release). PGE₂ is known to exacerbate joint inflammation (18) and induce IL-1β expression (23). Our experiments suggest that these inflammatory mediators (NO and PGE₂) may be involved in the disease process of OA. In rheumatoid disease, NO and PGE₂ could be expected to exert complex effects on chondrocytes as well as on the variety of cells involved in local and systemic immunological processes. In OA, on the other hand, these inflammatory mediators are likely to act in a more limited manner, exerting autocrine effects upon the metabolism of articular chondrocytes. For NO, the literature suggests that catabolic effects predominate, including the inhibition of proteoglycan and collagen synthesis as well as activation of metalloproteases (11, 12). For PGE₂, the net effects on chondrocytes are less clear. The quantity of PGE₂ produced could promote cartilage damage by exacerbating joint inflammation (18) and inducing IL-1β expression (23). However, exogenous PGE₂ added to rat chondrocytes stimulates [³H]thymidine incorporation and aggrecan synthesis (24). In human OA-affected cartilage, exogenous PGE₂ upregulates glucocorticoid receptors (25). These latter two studies suggest potential beneficial or reparative effects of PGE₂ on matrix homeostasis in cartilage.

The elucidation of the role of COX-2 expression in a variety of other tissues may also be relevant to an understanding of its role in OA. Recent studies by Tsujii and DuBois (26) have shown that overexpression of COX-2 in rat intestinal epithelial cells causes increased adhesion to extracellular matrix proteins, lack of E-cadherin expression, reduced expression of TGFβ₂ receptors, and resistance to butyrate-induced apoptosis with increased BCL-2 expression. Furthermore, additional evidence that the role of PGE₂ goes beyond that of a mere inflammatory mediator was obtained in experiments with COX-2 knockout mice, which showed high incidence of renal dysplasia, cardiac fibrosis, and infertility (in female mice) (27). Therefore, in view of the impact of PGE₂ levels (in transgenic and knockout systems) on various cellular functions, a reevaluation of its role in the current understanding of OA is warranted.

One of the most intriguing aspects of this study is that a pleiotropic molecule such as NO regulates another multifunctional mediator, PGE₂. Several studies in the literature indicate that NO (in the presence or absence of cytokines) enhances cyclooxygenase activity and PGE₂ production in various cell types including normal human chondrocytes (28–33). Salvemini et al. (34) have shown that injection of iNOS inhibitors into a rodent air pouch model (carrageenan-induced) blocked both iNOS and COX-2 activity in areas of inflammation. Our studies, in contrast, are similar to the studies by Stadler et al. (35) and Swierkosz et al. (36) that indicate that endogenous NO inhibits the synthesis of COX products as observed in rodent Kupffer cells and macrophages, respectively. This controversy may be due to the tissue-specific expression of NOS/COX-2 in various cell types, the difference in the pathophysiology of normal and OA-affected chondrocytes, and the influence of various other mediators in the microenvironment of the cartilage that may influence the production of NO and PGE₂. This is well demonstrated by Janabi et al. (37), where endogenous NO activated PGE₂ production in human microglial cells but not in astrocytes. Analysis of interactions between PGE₂ and NO showed that PGE₂ does not induce NO and is not required for NO induction by IL-1β (33). This latter observation is similar to those seen in this study. However, in contrast to studies

with OA-affected cartilage, exposure of normal chondrocytes to NO donors induced high levels of PGE₂, and NOS inhibitors (NMA) reduced the IL-1 β -induced PGE₂ production.

Our studies demonstrate for the first time the negative influence of NO on PGE₂ synthesis in human OA-affected cartilage in ex vivo conditions. Similarities in the induction of these two mediators are of interest. Both NOS and COX-2 are up-regulated in OA cartilage. In vitro, both enzymes are induced in chondrocytes by proinflammatory cytokines such as IL-1 and TNF- α . The production of both NO and PGE₂ by OA cartilage explants can be attenuated by inhibitors of protein synthesis (cycloheximide) and NF- κ B (PDTC). An interesting divergence in the regulation of COX-2 and NOS in chondrocytes, however, is reflected in their sensitivity to glucocorticoids: in OA chondrocytes expression of COX-2, but not NOS, is inhibited by prior exposure to dexamethasone (11, 38).

Overall, these observations indicate that PGE₂ in chondrocytes plays a significant physiological role in cartilage homeostasis. These studies, together with our recent observation that nonsteroidal antiinflammatory drugs such as aspirin (but not indomethacin or sodium salicylate) can inhibit NOS expression in a COX-2/PGE₂-independent fashion (21), indicate that drugs exhibiting selectivity towards both NOS and COX-2 may offer the potential for developing modified/new nonsteroidal antiinflammatory drugs with relatively little mechanism-based toxicity.

Acknowledgments

We thank Dr. Timothy Hla (American Red Cross, Rockville, MD) for generously providing the COX-2 cDNA, National Disease Research Interchange (Philadelphia, PA) for providing some of the tissues used in this study, and Ms. Ann Rupel for preparation of the manuscript.

References

- Hough, A.J., Jr. 1993. Pathology of osteoarthritis. In *Arthritis and Allied Conditions*. D.J. McCarty and W.J. Koopman, editors. Lea & Febiger, Philadelphia. 1699–1721.
- Howell, D.S., and J.P. Pelletier. 1993. Etiopathogenesis of osteoarthritis. In *Arthritis and Allied Conditions*. D.J. McCarty and W.J. Koopman, editors. Lea & Febiger, Philadelphia. 1723–1769.
- Crofford, L.J., R.L. Wilder, A.P. Ristimaki, H. Sano, E.F. Remmers, H.R. Epps, and T. Hla. 1994. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of IL-1 β , phorbol ester, and corticosteroids. *J. Clin. Invest.* 93:1095–1101.
- Denko, C.W. 1989. Osteoarthritis: a metabolic disorder. In *New Developments in Antirheumatic Therapy*. K.D. Rainsford and G.P. Velo, editors. Kluwer Academic Publishers, The Netherlands. 29–35.
- Bombardier, S., P. Cattani, G. Ciabattini, O. Di Munno, G. Paero, C. Patrono, E. Pinca, and F. Pugliese. 1981. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and non-steroidal anti-inflammatory drugs. *Br. J. Pharmacol.* 73:893–901.
- Davies, P., P.J. Bailey, M.M. Goldenberg, and A.W. Ford-Hutchinson. 1984. The role of arachidonic acid oxygenation products in pain and inflammation. *Annu. Rev. Immunol.* 2:335–357.
- Davies, P., and D.E. MacIntyre. 1992. Prostaglandins and inflammation. In *Inflammation: Basic Principles and Clinical Correlates*. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, New York. 123–137.
- Robinson, D.R., A.H. Tashjian, and L. Levine. 1975. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. *J. Clin. Invest.* 56:1181–1188.
- Palmer, R.M.J., M.S. Hickery, I.G. Charles, S. Moncada, and M.T. Bayliss. 1993. Induction of nitric oxide synthase in human chondrocytes. *Biochem. Biophys. Res. Commun.* 193:398–405.
- Geng, Y., F.J. Blanco, M. Cornelissen, and M. Lotz. 1995. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. *J. Immunol.* 155:796–801.
- Amin, A.R., P. DiCesare, P. Vyas, M. Attur, E. Tzeng, T.R. Billiar, S.A. Stuchin, and S.B. Abramson. 1995. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. *J. Exp. Med.* 182:2097–2102.
- Sakurai, H., H. Kohsaka, M.F. Liu, H. Higashiyama, Y. Hirata, K. Kanno, I. Saito, and N. Miyasaka. 1995. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. *J. Clin. Invest.* 96:2357–2363.
- McCartney-Francis, N., J.B. Allen, D.E. Mizel, J.E. Albina, Q.W. Xie, C.F. Nathan, and S.M. Wahl. 1993. Suppression of arthritis by an inhibitor of nitric oxide synthase. *J. Exp. Med.* 178:749–754.
- Stefanovic-Racic, M., K. Meyers, C. Meschter, J.W. Coffey, R.A. Hoffman, and C.H. Evans. 1994. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. *Arthritis Rheum.* 37:1062–1069.
- Anderson, G.C., S.D. Hauser, K.L. McGarity, M.E. Bremer, P.C. Isakson, and S.A. Gregory. 1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. *J. Clin. Invest.* 97:2672–2679.
- Gilliam, M.B., M.P. Sherman, J.M. Griscavage, and L.J. Ignarro. 1993. A spectrophotometric assay for nitrate using NADPH oxidation by *Aspergillus* nitrate reductase. *Anal. Biochem.* 212:359–365.
- Adams, M.E., D.Q. Huang, L.Y. Yao, and L.J. Sandell. 1992. Extraction and isolation of mRNA from adult articular cartilage. *Anal. Biochem.* 202:89–95.
- Bandara, G., and C.H. Evans. 1992. Intercellular regulation by synovio-cytes. In *Biological Regulation of the Chondrocytes*. M. Adolphe, editor. CRC Press, Boca Raton, FL. 205–222.
- Wu, K.K. 1995. Inducible cyclooxygenase and nitric oxide synthase. *Adv. Pharmacol.* 33:179–207.
- Ristimaki, A., S. Garfinkel, J. Wessendorf, T. Maciag, and T. Hla. 1994. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. *J. Biol. Chem.* 269:11769–11775.
- Amin, A.R., P. Vyas, M. Attur, J. Leszczynska-Piziak, I.R. Patel, G. Weissmann, and S.B. Abramson. 1995. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. *Proc. Natl. Acad. Sci. USA.* 92:1926–1930.
- Tetsuka, T., D. Daphna-Iken, S.K. Srivastava, L.D. Baier, J. DuMaine, and A.R. Morrison. 1994. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E₂ negatively modulates induction of nitric oxide synthase by interleukin 1. *Proc. Natl. Acad. Sci. USA.* 91:12168–12172.
- Lorenz, J.J., P.J. Furdon, J.D. Taylor, M.W. Verghese, G. Chandra, T.A. Kost, S.A. Haneline, L.A. Roner, and J.G. Gray. 1995. A cyclic adenosine 3',5'-monophosphate signal is required for the induction of IL-1 β by TNF- α in human monocytes. *J. Immunol.* 155:836–844.
- Lowe, G.N., Y.H. Fu, S. McDougall, R. Polendo, A. Williams, P.D. Benya, and T.J. Hahn. 1996. Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. *Endocrinology.* 137:2208–2216.
- Di Battista, J.A., J. Martel-Pelletier, J.M. Cloutier, and J.P. Pelletier. 1991. Modulation of glucocorticoid receptor expression in human articular chondrocytes by cAMP and prostaglandins. *J. Rheumatol.* 27:102–105.
- Tsujii, M., and R.N. DuBois. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell.* 83:493–501.
- Dinchuk, J.E., B.D. Car, R.J. Focht, J.J. Johnston, B.D. Jaffee, M.B. Covington, N.R. Contel, V.M. Eng, R.J. Collins, P.M. Czerniak, et al. 1995. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. *Nature (Lond.)* 378:406–409.
- Salvemini, D., T.P. Misko, J.L. Masferrer, K. Seibert, M.G. Currie, and P. Needleman. 1993. Nitric oxide activates cyclooxygenase enzymes. *Proc. Natl. Acad. Sci. USA.* 90:7240–7244.
- Corbett, J.A., G. Kwon, J. Turk, and M.L. McDaniel. 1993. IL-1 β induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. *Biochemistry.* 32:13767–13770.
- Hajjar, D.P., H.M. Lander, S.F.A. Pearce, R.K. Upmacis, and K.B. Pomerantz. 1995. Nitric oxide enhances prostaglandin-H synthase-1 activity by a heme-independent mechanism: evidence implicating nitrosothiols. *J. Am. Chem. Soc.* 117:3340–3346.
- Tetsuka, T., D. Daphna-Iken, B.W. Miller, Z. Guan, L.D. Baier, and A.R. Morrison. 1996. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. *J. Clin. Invest.* 97:2051–2056.
- Salvemini, D., M.G. Currie, and V. Mollace. 1996. Nitric oxide-mediated cyclooxygenase activation: a key event in the antiplatelet effects of nitrovasodilators. *J. Clin. Invest.* 97:2562–2568.
- Blanco, F.J., and M. Lotz. 1995. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE₂. *Exp. Cell Res.* 218:319–325.
- Salvemini, D., P.T. Manning, B.S. Zweifel, K. Seibert, J. Connor, M.G. Currie, P. Needleman, and J.L. Masferrer. 1995. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. *J. Clin. Invest.* 96:301–308.
- Stadler, J., B.G. Harbrecht, M. Di Silvio, R.D. Curran, M.L. Jordan, R.L. Simmons, and T.R. Billiar. 1993. Endogenous nitric oxide inhibits the syn-

thesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. *J. Leukocyte Biol.* 53:165–172.

36. Swierkosz, T.A., J.A. Mitchell, T.D. Warner, R.M. Botting, and J.R. Vane. 1995. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. *Br. J. Pharmacol.* 114:1335–1342.

37. Janabi, N., S. Chabrier, and M. Tardieu. 1996. Endogenous nitric oxide

activates prostaglandin $F_2\alpha$ production in human microglial cells but not in astrocytes. A study of interactions between eicosanoids, nitric oxide, and superoxide anion (O_2^-) regulatory pathways. *J. Immunol.* 157:2129–2135.

38. Amin, A.R., M. Attur, P. Vyas, G. Thakker, I. Patel, P. Patel, R. Patel, and S.B. Abramson. 1996. A novel mechanism of action of tetracyclines: effect on nitric oxide synthase. *Proc. Natl. Acad. Sci. USA.* 93:14014–14019.